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Abstract: 
Introduction: Aluminum contamination of parenteral nutrition solutions has been 
documented for three decades. It can result in elevated blood, bone, and whole body 
aluminum levels associated with neurotoxicity, reduced bone mass and mineral content, 
and perhaps hepatotoxicity. The primary aluminum source among parenteral nutrition 
components is glass-packaged calcium gluconate, in which aluminum concentration the 
past three decades has averaged ~ 4000 µg/L, compared to < 200 µg/L in plastic 
container-packaged calcium gluconate. A concern about plastic packaging is leaching of 
plasticizers, including phthalates, which have the potential to cause endocrine (male 
reproductive system) disruption and neurotoxicity. Methods: Aluminum was quantified in 
samples collected periodically over more than two years from three calcium gluconate 
sources used to prepare parenteral nutrition solutions; two packaged in glass (from 
France and the US) and one in plastic (from Germany); in a recently released plastic-
packaged solution (from the US); and in the two glass containers. Phthalate 
concentration was determined in selected samples of each product and leachate of the 
plastic containers. Results: The initial aluminum concentration was ~ 5000 µg/L in the 
two glass-packaged products and ~ 20 µg/L in the plastic-packaged product, and 
increased ~ 30, 50 and 100% over 2 years, respectively. The aluminum concentration in 
a recently released Calcium Gluconate Injection USP was ~ 320 µg/L. Phthalates were 
not detected in any calcium gluconate solutions or leachates. Conclusion: Plastic 
packaging greatly reduces the contribution of aluminum to parenteral nutrition solutions 
from calcium gluconate compared to the glass-packaged product. 
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What is known:  
 Aluminum is a contaminant of parenteral nutrition solutions.  
 Aluminum can cause neurotoxicity, reduced bone mass and mineral content, and 
perhaps hepatotoxicity. 
 Glass-packaged calcium gluconate is the primary aluminum source of parenteral 
nutrition solutions. 
 
What is new: 
 As received glass-packaged calcium gluconate provides aluminum in excess of the 
FDA’s recognized level that results in aluminum accumulation associated with 
central nervous system and bone toxicity. 
 Aluminum in calcium gluconate increases over two years of storage. 
 Calcium gluconate packaged in the tested plastic containers does not provide 
aluminum in excess of the FDA level or measurable phthalates (plasticizers with 
potential to cause male reproductive system disruption and neurotoxicity).    
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Introduction: 
Aluminum contamination of parenteral nutrition solutions has been a documented 
problem for three decades (1-4), which can result in elevated blood aluminum (5), 
increased body burden (5, 6), increased bone aluminum (7), neurotoxicity (8), reduced 
bone mass and mineral content (6, 9), and perhaps hepatotoxicity (10, 11). This led to a 
US FDA labeling requirement addressing this issue, which concludes that “patients with 
impaired kidney function, including premature neonates, who receive parenteral levels 
of aluminum at greater than 4 to 5 [micro]g/kg/day accumulate aluminum at levels 
associated with central nervous system and bone toxicity” (12). The primary source of 
aluminum in parenteral nutrition solutions is calcium gluconate, reported to contribute up 
to 88% vs. ~ 4% from phosphates (13), 88.7% (14), 78% to home parenteral nutrition 
solutions (15), 81 vs. 9% from sodium phosphate (16), ~ 50% (17), 80% to 98% (18), 80 
± 22% (19), the main source of aluminum (20), and highest amounts were provided by 
dextrose and calcium gluconate (21). The raw material was identified as one, but not 
the sole source (22). The aluminum primarily comes from glass packaging (23-26). 
Aluminum is added to the glass of containers of parenteral solutions to improve 
resistance to chemical attack and thermal shock (27).  
 
Table 1 shows the reported concentrations of aluminum in calcium gluconate used to 
prepare parenteral nutrition solutions. Most of these values indicate that the aluminum 
concentration in this product, when packaged in glass, has averaged ~ 4000 µg/L, and 
has not decreased over the past three decades. Excluding three high values there has 
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been a non-significant increase in the aluminum concentration in calcium gluconate 
packaged in glass over the past three decades (Figure 1).  
 
The average daily administration of aluminum to premature and term infants has been 
found to be 15 to 25 µg/kg (5, 39, 43, 44), or three to five times the upper boundary of 
the US FDA guideline, and even higher in Argentina (21). In the United States, until mid-
2015, Calcium Gluconate Injection USP had only been available in glass packaging. 
Pharmacists had few opportunities to minimize aluminum administration in parenteral 
nutrition solutions, limited to using the most recently obtained product, based on the 
assumption that the aluminum concentration increases over storage time in the glass 
container (4, 45), as shown by one study cited in Table 1 (40).  
 
A few reports have shown much less aluminum in calcium gluconate packaged in 
plastic containers (Table 1) (37, 40). There have been encouragements to abandon 
glass packaged calcium gluconate in favor of plastic packaging (20, 40). A concern 
about plastic packaging is the possibility that the product contains leached plasticizers, 
particularly phthalates such as DEHP (bis(2-ethylhexyl) phthalate, aka: di-2-ethylhexyl 
phthalate, diethylhexyl phthalate). Phthalates have the potential to cause endocrine 
(male reproductive system) disruption and neurotoxicity. Infants are the most 
susceptible population (46, 47). Plasticizers might present a hazard not inherent to 
glass containers, although the rubber stopper of glass vials could be a source. 
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The present study was conducted to quantify the aluminum concentration over the shelf 
life of representative calcium gluconate solutions used to prepare parenteral nutrition 
solutions, and to determine the initial aluminum concentration and the rate and extent of 
aluminum concentration increase over storage time. The concentration of phthalates, 
including DEHP, was determined to ascertain if calcium gluconate provided a risk from 
exposure to these plasticizers.  
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Methods:  
Multiple containers of calcium gluconate solutions used in the preparation of parenteral 
nutrition solutions were obtained from three sources in July, 2013; APP 
Pharmaceuticals, LLC, US, packaged in glass; C.D.M. Lavoisier, France, packaged in 
glass; and B. Braun, Germany, packaged in plastic. A single vial packaged in glass was 
obtained from Fresenius Kabi, LLC, US, in May, 2015. Approximately half of the 10 mL 
calcium gluconate contents of individual containers from APP Pharmaceuticals and B. 
Braun was clean poured into duplicate seven mL perfluoroalkoxy alkanes (PFA) vials at 
~ 1.5 month intervals from July 19, 2013 through August 25, 2015. The interval between 
sample transfers of the Lavoisier product was ~ every 3 months after the first three 
samples. The Fresenius Kabi product was similarly transferred on September 8, 2015. 
The duplicate calcium gluconate samples were analyzed by inductively coupled plasma 
- mass spectrometry (ICP-MS) to quantify their aluminum concentration. The aluminum 
content of one of the glass vials from APP Pharmaceuticals and one of the glass 
ampoules from Lavoisier was determined by ICP-MS. Selected calcium gluconate 
samples were analyzed by gas chromatography – mass spectrometry (GC-MS) to 
quantify 8 phthalates. Leachable phthalates from one of the B. Braun plastic containers 
and the Fresenius Kabi plastic container were determined by GC-MS. Details are 
reported in the Supplemental Information.   
 
Data analysis: 
Outliers of the ICP-MS analysis of aluminum in the calcium gluconate solutions were 
identified using the Grubb outlier test (http://graphpad.com/quickcalcs/Grubbs1.cfm) 
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subjecting all results for samples from the same source to the test. One sample of the 
Lavoisier, four samples of the B. Braun, and two water blanks were identified as outliers 
and were removed from further data analysis. The average aluminum concentration of 
the two-hundred fold diluted water blanks (0.45 µg/L) (S.D. = 0.14 µg/L) was subtracted 
from each two-hundred fold diluted calcium gluconate value. The average aluminum 
concentration of the duplicate (collected same day) samples was plotted against time, 
starting with time = 0 when the first samples were transferred from their original 
containers to the PFA vials (July 19, 2013). Linear regression of aluminum 
concentration versus time was determined using GraphPad Prism 6 (GraphPad 
Software, Inc., La Jolla, CA). The aluminum content of the glass containers was 
compared by a t-test. 
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Results:  
Aluminum analysis: 
The instrument detection limit was 0.068 µg/L aluminum. The method detection limit 
(accounting for required dilution) was 13.6 µg/L aluminum. Aluminum concentration in 
the two analytical duplicates was 111 and 116% of the original sample. Spike recovery 
was 104 and 106% for two samples. The aluminum concentration in all samples was 
greater than the instrument detection limit; the lowest was 0.29 µg/L in a water blank. 
Aluminum concentration in the calcium gluconate samples is shown in Figure 2. The 
slope of aluminum concentration versus time for the APP product was significantly 
different from zero (F (1,15) 58.35, P < 0.0001), for the Lavoisier product was not 
significantly different from zero (F (1,8) 3.75, P = 0.089), and for the B. Braun product 
was (F (1,14) 15.02, P < 0.0017). The aluminum concentration in the duplicate samples 
from the sole Fresenius Kabi sample collected September 8, 2015 averaged 318 µg/L. 
The aluminum concentrations in the glass vial from APP Pharmaceuticals and the glass 
ampoule from Lavoisier were not statistically different. 
 
Phthalate analysis: 
The blank samples had < 0.02 mg/L of the phthalates. DEHP recovery from spiked 
water and Calcium Gluconate Injection USP samples was 86 and 91%, respectively. 
Recovery of the other six phthalates ranged from 76 to 100% (mean = 89%). Recovery 
of the surrogates ranged from 69 to 98% (mean = 89%).  Recovery of p-terphenyl-d14, 
that eluted closest to most of the phthalates (20.92 minutes), was 89% from water, 93% 
from the Calcium Gluconate Injection USP blank, and ranged from 74 to 102% (mean = 
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93%) from the eight tested samples. Recovery of the other two surrogates ranged from 
69 to 98% from the blanks and 33 to 98% (mean = 80%) from the eight tested samples. 
The concentrations of the seven phthalates in the eight tested one mL dichloromethane 
extracts of four to five mL calcium gluconate were less than the lowest standard (0.1 
mg/L), therefore there was < 0.025 mg/L phthalates in all samples. No phthalates were 
detected in dichloromethane extracts of either the B. Braun or Fresenius Kabi container. 
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Discussion: 
The initial aluminum concentration in calcium gluconate in the APP vials and Lavoisier 
ampoules was ~ 4800 µg/L (Figure 2), slightly higher than the average reported 
aluminum concentration in calcium gluconate packaged in glass over the past three 
decades (Figure 1). A typical initial parenteral nutrition calcium dose for neonates is 2 
mEq/kg (48), which would be delivered in 4.3 mL of 10% calcium gluconate (0.465 
mEq/mL Ca). 4.3 mL of 4800 µg/L aluminum would deliver ~20 µg/kg/day aluminum, 
exceeding the FDA guideline of four to five µg/kg/day, and consistent with the average 
daily administration of aluminum to premature and term infants of 15 to 25 µg/kg, cited 
in the Introduction. The FDA’s labeling requirement that requires a statement of the 
maximum level of aluminum present at expiry on the container label of small volume 
parenteral drug products does not resolve the problem of aluminum contamination of 
parenteral nutrition solutions. It permits aluminum concentrations in small volume 
parenterals that result in aluminum concentrations in parenteral nutrition solutions in 
excess of aluminum accumulation associated with central nervous system and bone 
toxicity. The use of calcium gluconate solutions packaged in glass shortly after their 
receipt by the end user would not successfully address the aluminum contamination 
problem.  
 
Aluminum concentration increased over time, as previously reported (40). There is a 
significant slope (increase of aluminum concentration over time) for the APP product 
packaged in glass, but not the Lavoisier product also packaged in glass. The increase 
of aluminum in the Lavoisier product over time (~ 30%) was less than in the APP 
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product (~ 50%). The Lavoisier product contained ~ 7% calcium gluconate and 3% 
calcium glucoheptonate (aka gluceptate) compared to 10% calcium gluconate in the 
APP product. The binding affinity of gluconate for aluminum (49) is large enough to 
attribute the increase of aluminum over time in calcium gluconate to the leaching of 
aluminum from the glass containers. No aluminum glucoheptonate stability constant 
was found in the literature. As the structures of gluconate and glucoheptonate are very 
similar there is no reason to expect a significant difference in their aluminum binding 
affinities. The presence of calcium glucoheptonate in the Lavoisier product is unlikely to 
account for the difference in rate of aluminum increase in these products. The amount 
of aluminum in the glass vial from APP was not different from the glass ampoule from 
Lavoisier (Supplemental Information). Package inserts do not inform about the type of 
glass. The USP monograph for Calcium Gluconate Injection states that the solution 
should be preserved in single-dose containers, preferably of Type I glass. Type I glass 
is used to manufacture ampoules. It is not clear if there are differences in the glass 
composition of the APP and Lavoisier product containers that influenced the rate of 
aluminum increase over time in calcium gluconate stored in those containers.  
Irrespective of the glass source, using a calcium gluconate solution from a glass 
package that has been on the shelf for some time exacerbates the problem of aluminum 
contamination.    
 
Switching calcium gluconate from glass to plastic packaging does not remove all 
parenteral nutrition component sources of aluminum. Plastic packaged calcium 
gluconate contains measurable aluminum (Table 1 and results of this study). Other 
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components of parenteral nutrition solutions and intravenous therapy of neonates are 
also contaminated with aluminum. Three of concern are phosphates, heparin, and 
albumin. Table 2 contains the aluminum concentrations in phosphates, heparin, and 
albumin reported in the publications cited in Table 1. There are reports of aluminum 
concentrations in 18 phosphate solutions in which the phosphate concentration is 
sufficiently reported to calculate aluminum (in µg) in one mmol of phosphate (2, 17, 22, 
25, 28, 30, 33, 34, 41), the phosphate dose to initiate parenteral nutrition per kg patient 
body weight (48). The median aluminum concentration of the 18 solutions is 1400 µg/L, 
which would deliver 1.4 µg aluminum per mmol phosphate. Compared to the ~ 20 µg of 
aluminum from calcium gluconate that would be in parenteral nutrition solution for a 1 kg 
neonate (above), calcium gluconate is a greater contributor. The aluminum contribution 
from heparin to parenteral nutrition solutions is negligible, given its suggested 
concentration in parenteral nutrition solutions is 1 U/mL (48) . As albumin is not a 
routine component of parenteral nutrition solutions its contribution compared to calcium 
gluconate is not made. However, large, repeated albumin doses might present a 
significant amount of aluminum. 
 
The problem of aluminum contamination of calcium gluconate can be largely avoided by 
the use of plastic packaging, as has been suggested (20, 40). The present results 
support that suggestion.  
 
A concern for products packaged in plastic is the potential release of plasticizers from 
the container into the product. The phthalates are of particular concern, especially for 
infants. The maximum allowable dose for DEHP by intravenous injection to neonatal 
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infant boys (birth to 28 days of age) is 210 μg/day (50). Based on the typical initial 
parenteral calcium dose for a neonate of average weight (3.4 kg), which would be 
delivered in ~ 14.6 mL of 10% calcium gluconate, the maximum allowable level of 
DEHP in calcium gluconate is ~ 15 μg/mL. None of the samples had > 0.2% of this 
level.  
 
The results of the present study, and prior reports of aluminum contamination of calcium 
gluconate packaged in glass and plastic, and the lack of phthalate plasticizers in 
calcium gluconate packaged in plastic, support the suggestions that glass-packaged 
calcium gluconate should be avoided as a component of parenteral nutrition solutions 
delivered to patients with impaired kidney function. The recent introduction in the US of 
plastic container packaged calcium gluconate should enable the preparation of 
parenteral nutrition solutions with considerably reduced aluminum content, to the benefit 
of patients with impaired kidney function, including premature neonates.  
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Figure legends  
Figure 1. Aluminum concentration of calcium gluconate packaged in glass. The values 
are from Table 1 with the exclusion of 10,695 reported by (35) and values reported by 
(18). Line is best fit of the data points. 
 
 
Figure 2. Aluminum concentration in 10% calcium gluconate from single lots collected 
over time. Values are the mean of the duplicate samples collected on and after the date 
of the first sample (time = 0).  Note the different Y axis scale for the B. Braun product. 
Line is best fit of the results.  
 
Figure 1 Click here to download Figure Figure 1.tif 
Figure 2 left panel Click here to download Figure Figure 2 left.tif 
Figure 2 center panel Click here to download Figure Figure 2 center.tif 
Figure 2 right panel Click here to download Figure Figure 2 right.tif 
Table 1. Reported aluminum concentrations in calcium gluconate.  
Source (as stated in the reference) 
Aluminum 
concentration 
(µg/L) 
Reference 
Packaged in glass 
Calcium gluconate 10% 5056 (2) 
Calcium, Sandoz 3753 (28) 
Calcium gluconate, Lymphomed 2245 (range 2000 to 
2586) 
 
 
 
(13) 
Calcium gluconate, Invenex 2592 & 2610 
Calcium gluconate, Elkins Sinn 3973 (range 1095 to 
5565) 
Calcium gluconate, IMS 3299 
Calcium gluconate, American quinine 2286 
10% Calcium gluconate, Phoenix 3430 (29) 
Calcium gluconate 4850 (30) 
Ca gluconate, Lymphomed  2375 (range 2000 to 
2750) 
(31) 
Calcium gluconate 1100 to 5600 (14) 
Calcium gluconate 10%, Pharmacie Centrale AP Paris 675 & 1830  
(32) 
Calcium gluconate 10%, Arguettant 1890 
Calcium gluconicum, Braun 3825 (3) 
Calcium gluconate, Palex 5437 (33) 
Calcium gluconate 0.22 mmol/mL, David Bull Labs. Pty. Ltd.  5800 
(34) Calcium 10%, Sandoz 4900 
Calcium gluceptate 10% 4800 
 
 
Table 1
Table 1. Reported values of the aluminum concentration in calcium gluconate. (cont.)  
Calcium 10%, Braun  4734 & 6243 
(35) Calcium 20%, Braun 10,695 
Calcium-gluconat 10%, Pharma Hameln 4421 
Calcium gluconate 10%, Meram 5940 
(15) Calcium gluconate 10%, Aguettant 5940 
Calcium gluconate, AP Paris 6130 
Calcium gluconate, American Regent 4201 ± 267 (16) 
10% Calcium gluconate, Commercial Polfa 4400 (36) 
Calcium gluconate 10% (10 ml vial) 5000  
(37) Calcium gluconate 10% (100 ml vial) 3000 
Calcium gluconate 20% (10 ml vial) 6000  
Halex Istar (lot 1) 5621 
(22) 
Halex Istar (lot 2) 6781 
Ariston 5960 
B. Braun 4530 
Elkins Sinn 3987 
Calcium gluconate 10% 5621 & 5960 (25) 
Calcium gluconate 5%, PCH, Paris, France 680 (17) 
Calcium gluconate 10% 2712 (range 2240 to 
3040) 
(38) 
Calcium gluconate 10%, Hypofarma 9205 & 19,400 (18) 
Calcium gluconate 3234 (39) 
Calcium gluconate 10% (new) 4910 
(40) 
Calcium gluconate 10% (old) 6150 
 
 
Table 1. Reported values of the aluminum concentration in calcium gluconate. (cont.)  
Calcium gluconate 100 mg/ml, American Pharmaceutical Partners 2812 (range 1969 to 
3495) 
(41) 
Calcium gluconate 100 mg/ml, American Regent 2487 (range 1928 to 
2887) 
Calcium gluconate 10% range: 4000 to 4400 
(42) 
Calcium gluconate 10%, PISA Farmaceutica  3890 (20) 
Calcium gluconate 20% 4000 (range 3100 to 
4200) 
(21) 
Packaged in plastic 
Calcium gluconate 10%, Braun 105 
(37) 
Calcium gluconate 20%, Braun  195 
Calcium gluconate 10%  27 & 30 (new) 
31 & 33 (old) 
(40) 
 
Table 2. Reported aluminum concentrations (µg/L) in phosphates, heparin and albumin.  
Phosphate 
 
 
Heparin 
 
Albumin 
 
Reference 
Potassium phosphate 3 M 16,598  1000 U/mL 684 
5000 U/mL 359 
10,000 U/mL 468 
25% 1822 
(2) 
Sodium phosphate 3 M 5056  
Potassium phosphate 1 M  486  1296 (28) 
Potassium phosphate  92 & 2189 
(2069 to 2301) 
 25% 914 & 
2364 (1116 to 
5849) 
(13) 
Sodium phosphate 6 & 2236 (2026 
to 2370) 
Potassium acid phosphate 1882   (29) 
Potassium acid phosphate 13.6% 
(1 M) 
2154    
(30) 
Potassium phosphate 2754 (2025 to 
7128) 
  
(31) 
Sodium phosphate 65 (ND* to 284) 
Potassium phosphate 90 to 2300   
(14) 
Sodium phosphate < 5 to 2370 
  5% 164 
20% 28 
(3) 
Potassium phosphate 9539   
(33) 
Monopotassium phosphate 1 M 1533  
Dipotassium phosphate 1 M 3615  
Monosodium phosphate 1 M 1451  
 
 
 
Table 2
Table 2. Reported aluminum concentrations (µg/L) in phosphates, heparin and albumin. (cont.) 
Potassium acid phosphate 1 M  2387  
100 to 25,000 
U/mL  
6 to 31 
 
(34) 
Potassium dihydrogen phosphate 
0.54 g and di- potassium 
hydrogen phosphate 1.83 g in 10 
mL 
7689 
Potassium phosphate, Braun 18 & 188 Sodium heparin 
25,000 IE/5 mL  
70 
5% 90 ± 61 
20% 57 ± 45 (35) Potassium phosphate pfrimmer, 
Kabi 
2826 & 3421 
Sodium phosphates, American 
Regent 
6288   
(16) 
Potassium phosphates, not 
commercial 
9800   
(36) 
Sodium potassium phosphates, 
Addiphos Pharmacia 
13,000 to 41,600 
Potassium phosphate, Aster, B. 
Braun, & Fresenius, 2 mEq/mL  
689 ± 348 
 
5000 IU/mL 
 481 ± 275 
5000 IU/0.25 mL 
165 ± 27 
20% 94 & 235 
(22) 
Sodium phosphate, Abbott & 
Geyer, 0.5 M 
568 ± 320  
Potassium phosphate, 2 mEq/mL  988 & 1325  5000 IU/mL  
732 & 738 
20% 149 & 644 
(25) 
Sodium phosphate, 0.5 mol/L 879 & 933  
Dipotassium phosphate 1.7 M  240   (17) 
  Sodium heparin 
1% 108 (range 
106 to 112) 
20% 221 
(range: 195 to 
231) 
(38) 
 
 
Table 2. Reported aluminum concentrations (µg/L) in phosphates, heparin and albumin. (cont.) 
Potassium phosphate, American 
Pharmaceutical Partners 
8250   
(39) 
Sodium phosphate, American 
Regent 
622 
Potassium phosphate 3 M 4040 & 9972    
(41) 
Sodium phosphate 3 M 29 & 3242  
Potassium phosphate, PISA 
Farmaceutica 
3780   
(20) 
Sodium phosphate, PISA 
Farmaceutica 
1780 
Sodium phosphate  4460 (range 
4638 to 4809) 
  
(21) 
* = not detected 
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Supplemental Information to: Aluminum and phthalates in calcium gluconate; 
contribution from glass and plastic packaging 
 
Materials and Methods:  
Materials: 
Twenty-five 10 ml glass vials of Calcium Gluconate Injection, USP (APP 
Pharmaceuticals, LLC, Schaumburg, IL; Product Code 31110, NDC No. 63323-311-10, 
Lot 6005911, Expiration April, 2015), ten 10 ml glass ampoules of Gluconate de 
Calcium Lavoisier 10% (C.D.M. Lavoisier, 75017 Paris, France; Lot 2A154, Expiration 
September, 2015), and twenty 10 ml plastic ampulles of Calciumgluconat 10% B. Braun 
Injektionslösung (B. Braun Melsungen AG – 34209 Melsungen, Deutschland; Lot 
12417011; Expiration September, 2015) were obtained in July, 2013. One 10 plastic vial 
of Calcium Gluconate Injection, USP (Fresenius Kabi, LLC, Lake Zurich, IL; Product 
Code 31110, NDC No. 63323-311-19, Lot 6009399, Expiration March, 2016), was 
obtained in May, 2015. EPA Method 506 Phthalates Mixture containing bis(2-ethylhexyl) 
adipate, bis(2-ethylhexyl) phthalate (DEHP), butyl benzyl phthalate, di-n-butyl phthalate, 
dimethyl phthalate, diethyl phthalate, and di-n-octyl phthalate (Ultra Scientific); an 
internal standard mix containing acenaphtene-d10, chrysene-d12, 1,4-dichlorobenzene-
d4, naphthalene-d8, perylene-d12, and phenanthrene-d10 (Restek); and an EPA 
Method 3500 (SW-846) and CLP–Semi-Volatiles Base/Neutrals Surrogates mixture 
containing 2-fluorobiphenyl, nitrobenzene-d5, and p-terphenyl-d14 (Restek) were 
obtained from VWR. 
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Methods: 
Sample collection: 
Approximately half of the 10 ml calcium gluconate contents of individual containers from 
APP Pharmaceuticals and B. Braun was clean poured into duplicate seven ml 
perfluoroalkoxy alkanes (PFA) vials (Savillex, Eden Prairie, MN) at ~ 1.5 month 
intervals. Approximately half of the 10 ml contents of ampoules from C.D.M. Lavoisier 
was clean poured into duplicate seven ml PFA vials at ~ 1.5 month intervals initially, 
then ~ at three month intervals. Approximately half of the 10 ml contents of the 
Fresenius Kabi product was clean poured into duplicate seven ml PFA vials September 
8, 2015. Sample transfer was conducted in a Class 100 laminar flow hood. The PFA 
vials had been pre-cleaned by soaking in 10% nitric acid then 5 mm EDTA, and triple 
rinsed with 18.2 MΩ-cm water. Water (18.2 MΩ-cm) from a Barnstead NANOpure water 
polishing system, stored in a 500 ml FEP bottle that had been triple cleaned with trace 
metal grade nitric acid, was clean-poured into duplicate PFA vials on many of the same 
occasions calcium gluconate samples were transferred, to serve as a blank. All samples 
before and after transfer to PFA vials were stored at room temperature throughout the 
study.  
 
Aluminum quantification in calcium gluconate solutions by ICP-MS:  
Immediately prior to analysis, samples were heated to solubilize precipitation and then 
diluted two-hundred-fold with 1% (v/v) concentrated ultra-pure nitric acid.  Results were 
compared to a standard curve created from an Inorganic Ventures (Christiansburg, VA, 
USA) multi-element ICP-MS standard. To validate the calibration curve, a standard of 
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known concentration was prepared from a multi-element standard of a different lot 
number and analyzed as an unknown. Two samples were diluted and analyzed a 
second time as sample dilution replicates. Spike recovery was determined by adding 10 
µL of the 10 mg/L calibration standard to two 10 mL samples, adding 10 µg/L aluminum. 
Scandium was added as the internal standard to all samples and standards for the 
aluminum analyses at the same concentration (approximately five µg/L). The instrument 
detection limit was calculated as three times the standard deviation of the eleven 
reagent blanks. Care was taken to minimize metal contamination, including use of 
metal-free centrifuge tubes, trace metal grade nitric acid, and 18.2 MΩ-cm water. All 
dilution procedures were conducted in a class 100 laminar flow hood. Samples were 
analyzed by ICP-MS (Agilent 7500cx, Santa Clara, CA, US). 
 
Aluminum analysis of glass vials by laser ablation ICP-MS: 
A glass vial that contained Calcium Gluconate Injection, USP from APP 
Pharmaceuticals and a glass ampoule that contained Gluconate de Calcium from 
Lavoisier were wrapped in paper and shattered using a hammer.  Samples from the 
bottom of each vial were collected and rinsed thoroughly with deionized water.  The 
samples were them mounted on microscope slides using double sided tape with the 
inside surface of the bottom of the vials facing up.  The samples were analyzed using a 
213 nm laser ablation system (CETAC Technologies LSX-213, Omaha, NE, USA) 
coupled to an inductively coupled plasma mass spectrometer (Agilent Technologies 
7500CX, Santa Clara, CA, USA).  Duplicate samples from each vial were ablated with 
100 laser shots at a frequency of 20 Hz within a 200 µm spot. Standardization was 
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performed by ablating standards with known aluminum concentrations in a calcium 
carbonate matrix in the same manner.  These standards were prepared by mixing a 
known mass of aluminum contained within an ICP-MS standard solution (Inorganic 
Ventures, Christiansburg, VA, USA) with a known mass of calcium carbonate, drying 
the mixture, and pressing it into pellets with a pellet press.  We were not able to make or 
obtain standards with a glass matrix that had known aluminum concentrations.  
Consequently, although the numbers are precise, they may not be accurate because 
laser ablation is highly matrix dependent. The true aluminum concentration may be 
different by as much as 10-fold. The aluminum concentration in the glass of the glass 
vial from APP was 2082 ± 170 (SD) mg/kg (~ 0.2%) and in the glass of the glass 
ampoule from Lavoisier: 2224 ± 228 (SD) mg/kg (~ 0.2%). These results indicate there 
was no significant difference in the aluminum concentration between these two 
containers, but must not be cited as accurate determinations of aluminum 
concentration. Reports of the aluminum concentration in glass vials include 5.8% Al2O3 
(or 3.1% Al) in Type I USP borosilicate hard glass and 1.9% Al2O3 (or 1% Al) in Type II 
USP soft glass (1), 0.61 to 3.01% aluminum (2), and 5% Al2O3 (or 2.6% Al) in Type I 
USP glass (3). 
 
Phthalate analysis in calcium gluconate solutions by gas chromatography – mass 
spectrometry: 
A method was developed based on a modification of EPA method 8270D that separated 
the seven components of the phthalates mixture, with retention times from 12.95 to 
25.12 minutes. DEHP eluted at 23.65 minutes. The method also separated the 
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phthalates from the six internal standard components, which had retention times from 
6.74 to 26.49 minutes, and the three surrogates, which had retention times from 7.85 to 
20.92 minutes. A calibration curve was prepared containing 0.1, 1.0, 2.5, 5.0, 7.5, and 
10 ppm phthalates. Five blanks were prepared (water, water exposed to pipette tip from 
the lot used to prepare the dilutions of calcium gluconate for ICP-MS aluminum 
quantification [above], Calcium Gluconate Injection USP, Calcium Gluconate Injection 
USP in PFA vial, and Calcium Gluconate Injection USP exposed to pipette tip). 
Phthalate recovery was determined from water and Calcium Gluconate Injection USP in 
PFA vials, by addition of 5 ppm phthalates. Samples of 10% calcium gluconate from 
APP Pharmaceuticals, Lavoisier, and B. Braun from the last collection date (August 25, 
2015) and the Fresenius Kabi sample were analyzed for their phthalate content. Five µL 
of 1000 ppm surrogate mix was added to the blanks, spiked samples, and 10% calcium 
gluconate samples (four to five ml) which were then extracted by adding three ml 
dichloromethane, shaken vigorously for five minutes, then transferring the organic layer 
to a separate vial. The extraction step was repeated and the extracts were combined 
and evaporated under a gentle stream of nitrogen to near dryness, the vial was rinsed 
and brought to a final volume of one ml with dichloromethane.  Two µL of 2000 ppm 
internal standard mix was added to each of the extracts and calibration curve 
components. The samples were analyzed on a Varian CP-3800 GC with a Varian 
Saturn 2200 MS. 
 
Phthalate analysis in leachates from plastic containers by gas chromatography – mass 
spectrometry: 
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The B. Braun plastic container that provided the last measured sample, on August 25, 
2015, and the Fresenius Kabi plastic container were used to determine if phthalates 
would leach from the plastic. A portion of the bottom of each container was removed 
and weighed (B. Braun 0.311 g; Fresenius Kabi 0.371 g) and placed in 24 ml vials with 
five ml of dichloromethane. The vials were agitated by sonication and vortex mixing for 
10 minutes. One ml of the extract was transferred to an autosampler vial adding two µL 
of internal standard mix. Samples were analyzed by GC-MS as described above for the 
detection of phthalates. 
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